Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs
BOSTON and ATLANTA, April 18, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today issued a Letter to Shareholders.
- BOSTON and ATLANTA, April 18, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today issued a Letter to Shareholders.
- Dear Fellow Shareholders of Inhibikase Therapeutics:
2024 has been off to a productive start for Inhibikase. - Our 201 Trial is approximately 75% enrolled, with the last patient anticipated to enter the trial in June.
- We have only 30 patients left to enroll as of April 18, 2024, and we expect to complete enrollment in approximately mid-June.